{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000102","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.156534+00:00","generated_at":"2026-05-29T04:08:05.944728+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keros halts two high-dose arms of Phase 2 PAH trial after pericardial effusion","bullets":["Voluntarily halted dosing in 3.0 mg/kg and 4.5 mg/kg cibotercept arms in ongoing TROPOS trial.","Decision based on unanticipated pericardial effusion adverse events; safety review triggered.","1.5 mg/kg treatment arm continues dosing after DMC and internal risk-benefit assessment.","Topline data from all treatment arms still expected in Q2 2025; FDA and other regulators notified.","CEO Jasbir Seehra stated patient safety is top priority; Company investigating findings."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000102","json":"https://secwatch.observer/filing/0001664710-24-000102.json","markdown":"https://secwatch.observer/filing/0001664710-24-000102.md","text":"https://secwatch.observer/filing/0001664710-24-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000102/0001664710-24-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000102/kros-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:08:05.944728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}